-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
"We are increasing our 12 month price target to $2.34 from the $1.50 to 1.75 range based on our Sum-of-The-Parts valuation analysis which is supported by a combination of quantitative valuation methods including a “company comparable” analysis even though ACTC.OB’s are presently at the developmental or pre-clinical stage. We believe shares of ACT offer meaningful upside both in the near and long term. We note that ACTC.OB has constructed a vast patent estate with ownership or exclusive licensing of greater than 30 issued patents and over 280 patent applications in the field of stem cells and regenerative medicine."
gonna take some volume on the plus side to keep it up much less make a run to those levels. keep an eye on the filings imo.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
long range potential and starting to increase revs keeps me in this. they still have way too much dependence on funding but - when they can stretch their legs on their own look out. of course taking profits on the runs and re-loading on the dips is the way to play along the way.
IMO
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Advanced Cell Technology's General Counsel, Jonathan F. Atzen, Interviewed on Bloomberg Television Friday April 27, 10:21 am ET Comments on Legislative and Legal Environment for Scientific Research on "In Focus"
ALAMEDA, Calif.--(BUSINESS WIRE)--Advanced Cell Technology, Inc.'s (OTCBB: ACTC - News) Senior Vice President and General Counsel, Jonathan F. Atzen, was interviewed by Bloomberg Television yesterday about the legislative and regulatory climate as it affects human embryonic stem cell (hESC) research and development, in a live, five minute interview on the new "in-house counsel" segment of the popular show "in focus." ADVERTISEMENT
Asked about the regulatory hurdles faced by Advanced Cell Technology and other human embryonic stem cell research entities, Mr. Atzen replied, "The difficulty in our business right now from a regulatory perspective revolves around the lack of federal regulation, or leadership, at the federal level. What we're really faced with now is the states filling in on the regulatory side, in terms of funding and in terms of the derivation of these materials."
On the subject of state support of human embryonic stem cell research, particularly in California and Massachusetts, Mr. Atzen said, "Interestingly enough, and probably not by coincidence, we're headquartered in California and have a very important facility in Massachusetts, as well. These are two of the states that are most progressive."
Asked if he sees more states becoming more supportive of hESC research, Mr. Atzen struck an optimistic note. He listed various states which have or are considering pro-stem cell research legislation, such as New York, Connecticut, and Illinois, and reflected, "This is a groundswell. It's a state effort that has taken the place of efforts on the federal level which have not taken effect yet."
Mr. Atzen commented on stem cell patent law, as well, saying, "It's great to be a lawyer in the stem cell industry. Patent law obviously drives our industry... there's a great landscape of IP (intellectual property) out there right now. It's a competitive landscape, and we compete in it aggressively."
Advanced Cell Technology recently announced a collaborative program with the Casey Eye Institute at the Oregon Health & Science University, on its leading indication, its retinal pigment epithelial (RPE) program. The company plans to file an investigational new drug application (IND) with the FDA for this program, which has been demonstrated to rescue vision in blind rats. Moreover, the company expects to file INDs for its hemangioblast cell lines for blood and cardiac disorder, and for its dermal cell lines for skin and wound repair, next year.
A streaming video of the interview will be accessible later today on Advanced Cell's website: http://www.advancedcell.com.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the annual report on Form 10-KSB for the fiscal year ending December 31, 2007.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Contact: The Investor Relations Group Investors: James Carbonara or Joseph Kessler, 212-825-3210 or Media: Bill Douglass, 212-825-3210
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
**********: ACTC, CFPC, CGLD, PLRS Have Also Been Added To Naked Short List Today Tuesday 05/01/2007 9:14 AM ET - M2 **********, www.**********, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE naked short threshold list: Advanced Cell Technology Inc. (OTCBB: ACTC), Coffee Pacifica Inc. (OTCBB: CFPC), Capital Gold Corp. (OTCBB: CGLD), Pluristem Life Systems Inc. (OTCBB: PLRS). For a complete list of companies on the naked short list please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to www.**********.
buy ins.net
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Advanced Cell Technology and Wisconsin Alumni Research Foundation Announce Commercial License Agreement Wednesday May 2, 5:01 pm ET Agreement Represents Progress Toward Commercial Product Development
ALAMEDA, Calif.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB:ACTC - News) today announced an expanded, non-exclusive commercialization agreement with Wisconsin Alumni Research Foundation (WARF). The expanded agreement grants Advanced Cell rights to the commercial use of human embryonic stem cells (hESCs) to develop human therapies, with the exception of neuronal, pancreatic beta cells, and cardiac applications, and enables the marketing of a broad array of research products. This agreement bolsters Advanced Cell's existing patent estate which currently consists of over 380 owned or licensed patents and patent applications worldwide by granting commercial access to an additional 150 important stem cell technology patents and patent applications.
"We believe that the expanded license will afford our company greater flexibility and accelerate the process of bringing ACT's therapeutic programs toward human clinical trials and, ultimately, to commercial adoption and bedside use." said Michael D. West, Ph.D., President and Chief Scientific Officer of Advanced Cell Technology. "The combination of these technologies and the rapidly-growing pipeline coming from our ACTCellerate platform lead us to believe that other clinical applications, in addition to our current target indications, are feasible. These additional therapies include treatment for disorders of the endocrine, craniofacial, muscle, bone, cartilage, liver, kidney, and respiratory systems."
"We have a long history of collaboration with WARF dating back to when our company's president, Dr. West, the founder of Geron Corporation, facilitated the collaboration with Dr. James Thompson at the University of Wisconsin that led to the isolation of the human embryonic stem cell. The addition of these important WARF patents further strengthens ACT's existing broad intellectual property rights in hESC technology," said William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology.
Additional details regarding the commercial license agreement with WARF will be included in a Current Report on Form 8-K to be filed by the Company with the Securities and Exchange Commission.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Wisconsin Alumni Research Foundation supports world-class research at the University of Wisconsin-Madison by protecting the intellectual property of University faculty, staff and students, and by licensing inventions resulting from their work. Through the licensing efforts, university ideas benefit the public by bringing resources back to the University to continue the cycle of investment, research and invention. Established in 1925, WARF was the first university technology transfer office in the United States.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Looking for a downward trend myself. Keeping my eyes on it though. may turn quickly if they get the right news.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Precursor Cells Generated From Human Embryonic Stem Cells Show Ability to Repair Vascular Damage in Animals BusinessWire - May 07, 2007 1:08 PM ET
Related Quotes Symbol Last Chg ACTC Trade 0.745 +0.105 Real time quote.
Advanced Cell Technology, Inc. (OTCBB: ACTC) reported for the first time that hemangioblast precursor cells derived from human embryonic stem (hES) cells can be used to achieve vascular repair. The research, which appears today online (ahead of print) in the journal Nature Methods, by Advanced Cell Technology (ACT) and its collaborators, describes an efficient method for generating large numbers of bipotential progenitors--known as hemangioblasts--from hES cells that are capable of differentiating into blood vessels, as well as into all blood and immune cell lineages.
"The ability to repair vascular damage using these cells could have a profound impact on a large number of diseases that are major human afflictions," said Robert Lanza, M.D., Vice President of Research & Scientific Development at ACT, and senior author of the study. "Our results suggest the possibility of using nature's early cellular developmental components to restore vascularization and function in patients with vascular disease. An injection of these cells may be able to prevent a patient from having a leg amputated or from dying after a heart attack."
"We have developed for the first time a simple and highly scalable source of human hemangioblasts," stated Shi-Jiang Lu, Ph.D., Director of Differentiation at ACT and first author of the paper. "These proprietary cells represent a new and distinctly different population of cells that can be differentiated into vascular structures and multiple hematopoietic cell types. The elimination of serum and other animal components from the system, as well as the ability to generate an unlimited supply of these cells, will be important for future preclinical and human studies."
When the cells were injected into animals that had damage to their retina due to diabetes or ischemia-reperfusion injury (lack of adequate blood flow) of the retina, the cells homed to the site of injury and showed robust reparative function of the entire damaged vasculature within 24-48 hours. The cells showed a similar regenerative capacity in animal models of both myocardial infarction (50% reduction in mortality rate) and hind limb ischemia, with restoration of blood flow to near normal levels.
"These cells were able to generate functional blood vessels in the presence of severe tissue injury, as well as in chronic disease states," says Maria Grant, M.D., Professor of Pharmacology at the University of Florida, and an author on the paper. "These cells have a robust vascular reparative ability under what is typically considered very adverse growth conditions making them potentially ideal for treatment of diabetic vascular complications where profound tissue compromise exists and healing is typically severely compromised."
"While the cells in this study were tested in animal models, we believe this breakthrough has the potential to benefit many Americans suffering from vascular disease," stated William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology. "ACT is committed to moving this technology from the laboratory into the clinic. We plan on filing an Investigational New Drug Application with the Food and Drug Administration for the first clinical application of these cells by the end of next year."
The researchers of the paper from Advanced Cell Technology collaborated with scientists from the University of Florida, Gainesville, Florida, and the Memorial Sloan-Kettering Cancer Center (MSKCC), New York, New York. The paper's other authors are Qiang Feng of ACT, Sergio Caballero of the University of Florida, and Yu Chen and Malcolm A.S. Moore, DPhil, of MSKCC.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the annual report on Form 10-KSB for the fiscal year ending December 31, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media FD Robert Stanislaro, 212-850-5657 or Investors The Investor Relations Group Joseph Kessler or James Carbonara 212-825-3210
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
Precursor Cells Generated From Human Embryonic Stem Cells Show Ability to Repair Vascular Damage in Animals Monday May 7, 1:08 pm ET -New, scalable population of hemangioblast cells halves the death rate following heart attack and repairs ischemic limbs and damaged vasculature-
WORCESTER, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB: ACTC - News) reported for the first time that hemangioblast precursor cells derived from human embryonic stem (hES) cells can be used to achieve vascular repair. The research, which appears today online (ahead of print) in the journal Nature Methods, by Advanced Cell Technology (ACT) and its collaborators, describes an efficient method for generating large numbers of bipotential progenitors--known as hemangioblasts--from hES cells that are capable of differentiating into blood vessels, as well as into all blood and immune cell lineages.
"The ability to repair vascular damage using these cells could have a profound impact on a large number of diseases that are major human afflictions," said Robert Lanza, M.D., Vice President of Research & Scientific Development at ACT, and senior author of the study. "Our results suggest the possibility of using nature's early cellular developmental components to restore vascularization and function in patients with vascular disease. An injection of these cells may be able to prevent a patient from having a leg amputated or from dying after a heart attack."
"We have developed for the first time a simple and highly scalable source of human hemangioblasts," stated Shi-Jiang Lu, Ph.D., Director of Differentiation at ACT and first author of the paper. "These proprietary cells represent a new and distinctly different population of cells that can be differentiated into vascular structures and multiple hematopoietic cell types. The elimination of serum and other animal components from the system, as well as the ability to generate an unlimited supply of these cells, will be important for future preclinical and human studies."
When the cells were injected into animals that had damage to their retina due to diabetes or ischemia-reperfusion injury (lack of adequate blood flow) of the retina, the cells homed to the site of injury and showed robust reparative function of the entire damaged vasculature within 24-48 hours. The cells showed a similar regenerative capacity in animal models of both myocardial infarction (50% reduction in mortality rate) and hind limb ischemia, with restoration of blood flow to near normal levels.
"These cells were able to generate functional blood vessels in the presence of severe tissue injury, as well as in chronic disease states," says Maria Grant, M.D., Professor of Pharmacology at the University of Florida, and an author on the paper. "These cells have a robust vascular reparative ability under what is typically considered very adverse growth conditions making them potentially ideal for treatment of diabetic vascular complications where profound tissue compromise exists and healing is typically severely compromised."
"While the cells in this study were tested in animal models, we believe this breakthrough has the potential to benefit many Americans suffering from vascular disease," stated William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology. "ACT is committed to moving this technology from the laboratory into the clinic. We plan on filing an Investigational New Drug Application with the Food and Drug Administration for the first clinical application of these cells by the end of next year."
The researchers of the paper from Advanced Cell Technology collaborated with scientists from the University of Florida, Gainesville, Florida, and the Memorial Sloan-Kettering Cancer Center (MSKCC), New York, New York. The paper's other authors are Qiang Feng of ACT, Sergio Caballero of the University of Florida, and Yu Chen and Malcolm A.S. Moore, DPhil, of MSKCC.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Advanced Cell Technology, Inc. Mid-Quarter Review Issued by Scimitar Equity Research, Inc.
May 8, 2007 09:39:00 (ET)
BOSTON, May 8, 2007 /PRNewswire via COMTEX/ -- Scimitar Equity Research, Inc. today issued aQ4/06 Analyst Review on Advanced Cell Technology, Inc. (ACTC, Trade ) entitled, "'Hemangioblast' Precursor Cells Produced From Human Embryonic Stem Cells Show Remarkable Ability to Repair Vascular Damage in Animals".
Advanced Cell Technology (ACT) is a biotechnology company applying human embryonic stem (hES) cell technology in the emerging field of regenerative medicine. ACT is developing novel stem cell-based treatments and cures to target a variety of serious diseases and injuries. ACTC's lead therapeutic development programs include stem cell based treatments for retinal disease such as macular degeneration; diseases of the blood, heart and circulatory system, and dermatological treatments for repair of skin damage from surgery, wounds and burns. ACT has entered development partnerships with leading institutions, and is pursuing additional partnerships with leading biotechnology companies and organizations worldwide.
The analyst research review of ACTC is available on Scimitar's website: www.scimitarequity.com .
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information, please visit: www.advancedcell.com . For investor-specific information and resources, visit
Scimitar Equity Research, Inc. provides sponsored equity research of the healthcare industry for the institutional and investment communities. We certify that all the views expressed in this review, accurately reflect our personal views about Advanced Cell Technology (ACTC, Trade ) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review does not have regard to the specific investment objectives, financial situation and the information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures.
CONTACT: Scimitar Equity Research, Inc. Henry W. McCusker Director of Research phone: (617) 559-1080 fax: (617) 559-1083 e-mail: hwm*scimitarequity.com
SOURCE Scimitar Equity Research, Inc.
Henry W. McCusker, Director of Research for Scimitar Equity Research, Inc., +1-617-559-1080, +1-617-559-1083 (fax), hwm*scimitarequity.com
posted
Advanced Cell Technology's Vice President of Research & Scientific Development to Present at the Life Science Institute's Symposium on Wednesday, May 9, 2007
May 9, 2007 10:26:22 (ET)
ALAMEDA, Calif., May 09, 2007 (BUSINESS WIRE) -- Advanced Cell Technology's (ACTC, Trade ) Vice President of Research and Scientific Development, Dr. Robert Lanza, will be highlighting the company's recent discovery that shows precursor cells, generated from human embryonic stem cells, have the ability to repair vascular damage in animals.
William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology stated, "We consider this to be the most exciting and significant scientific news that our company has ever produced. While the cells in this study were tested in animal models, we believe this breakthrough has the potential to benefit thousands of people suffering from vascular disease ACT is committed to moving this technology from the laboratory into the clinic. Further, we plan on filing an Investigational New Drug Application with the Food and Drug Administration for the first clinical application of these cells by the end of next year."
Dr. Lanza's presentation will take place at The University of Michigan's International Life Sciences Institute in a symposium titled "Frontiers in Stem Cell Biology". Immediately following the symposium, the slides used in Dr. Lanza's presentation may be found on the company's website at www.advancedcell.com .
About The International Life Sciences Institute
Founded in 1978, the International Life Sciences Institute (ILSI) is a nonprofit, worldwide foundation that seeks to improve the well being of the general public through the advancement of science. Its goal is to further the understanding of scientific issues relating to nutrition, food safety, toxicology, risk assessment, and the environment by bringing together scientists from academia, government, and industry.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the annual report on Form 10-KSB for the fiscal year ending December 31, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media The Investor Relations Group Bill Douglass, 212-825-3210 or Investors The Investor Relations Group Joseph Kessler or James Carbonara 212-825-3210
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Advanced Cell Technology's CEO to Present at Rodman & Renshaw 4th Annual Global Healthcare Conference
May 9, 2007 10:33:15 (ET)
ALAMEDA, Calif., May 09, 2007 (BUSINESS WIRE) -- Advanced Cell Technology (ACTC, Trade ), a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine, will be presenting at Rodman & Renshaw's 4th Annual Global Healthcare Conference in Monte Carlo, Monaco on Monday, May 14th at 5:00 PM local time (11:00 AM EST).
William M. Caldwell, IV, Chairman and CEO, will be providing an update on the Company's developments and business strategy. Further, Mr. Caldwell will be highlighting the company's recent groundbreaking discovery that shows precursor cells, generated from human embryonic stem cells, have the ability to repair vascular damage in animals.
"The ability to repair vascular damage using these cells could have a profound impact on a large number of diseases that are major human afflictions," said Robert Lanza, M.D., Vice President of Research & Scientific Development at ACT, and senior author of the study. "Our results suggest the possibility of using nature's early cellular developmental components to restore vascularization and function in patients with vascular disease. An injection of these cells may be able to prevent a patient from having a leg amputated or from dying after a heart attack."
The Conference will include presentations by over 200 companies, as well as experts from the medical, scientific and investment communities. Mr. Caldwell will be available to meet one-on-one with investors throughout the Conference.
A live audio web cast of this presentation can be accessed via: http://www.wsw.com/webcast/rrshq11/mchm . Further, you can access additional information about Advanced Cell and an audio replay of the presentation on this site for 90 days after the conference.
About Rodman & Renshaw
Rodman & Renshaw, LLC is a privately held, full-service investment bank committed to fostering the long-term success of emerging growth companies through capital raising, strategic advice, insightful research, and the development of institutional support.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the annual report on Form 10-KSB for the fiscal year ending December 31, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Media Bill Douglass, 212-825-3210 or Investors Joseph Kessler or James Carbonara 212-825-3210
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Advanced Cell Technology, Inc. Applauds California Supreme Court's Decision Regarding $3 Billion Stem Cell Research Program, Proposition 71
May 17, 2007 09:36:19 (ET)
ALAMEDA, Calif., May 17, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) applauds the $3 Billion Stem Cell Research Program, Proposition 71, upheld yesterday by the California Supreme Court. In a "request denied" ruling, the California Supreme Court declined to review the challenge brought forward by opponents of the measure.
The challenge to Proposition 71 was not upheld by the state appellate court in February of this year. It was then brought before the state Supreme Court, which yesterday declined to consider the petitions.
William M. Caldwell, IV, Chairman and Chief Executive Officer of Advanced Cell Technology, commented, "California voters made their intentions clear three years ago by voting for Proposition 71: they want California to be in the forefront of supporting stem cell research, which has the potential to cure a host of diseases and degenerative conditions. Yesterday, at long last, the final roadblock to implementing the will of the people of the Golden State has been cleared. Yesterday's decision means that California is now on its way to becoming the world's single largest backer of stem cell research. Indeed, the state could start issuing bonds in the very near future."
Mr. Caldwell continued, "Advanced Cell Technology is fortunate to be headquartered in the great state of California as we work to accelerate the transition of our stem cell therapies to the bedside."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: Joseph Kessler or James Carbonara, 212-825-3210 or Media: Bill Douglass, 212-825-3210 or Public Affairs: Chad Griffin Consulting, Inc. 310-888-3523
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Cool]](cool.gif)
![[Big Grin]](biggrin.gif)
![[Eek!]](eek.gif)
HOPE WE DONT SEE IT, BUT IM READY!![[Wink]](wink.gif)
![[Razz]](tongue.gif)
